Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer
- Autores
- Lamb, Caroline Ana; Fabris, Victoria Teresa; Jacobsen, Britta M.; Molinolo, Alfredo; Lanari, Claudia Lee Malvina
- Año de publicación
- 2018
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- There is a consensus that progestins and thus their cognate receptor molecules, the progesterone receptors (PRs), are essential in the development of the adult mammary gland and regulators of proliferation and lactation. However, a role for natural progestins in breast carcinogenesis remains poorly understood. A hint to that possible role came from studies in which the synthetic progestin medroxyprogesterone acetate was associated with an increased breast cancer risk in women under hormone replacement therapy. However, progestins have also been used for breast cancer treatment and to inhibit the growth of several experimental breast cancer models. More recently, PRs have been shown to be regulators of estrogen receptor signaling. With all this information, the question is how can we target PR, and if so, which patients may benefit from such an approach? PRs are not single unique molecules. Two main PR isoforms have been characterized, PRA and PRB, which exert different functions and the relative abundance of one isoform with respect to the other determines the response of PR agonists and antagonists. Immunohistochemistry with standard antibodies against PR do not discriminate between isoforms. In this review, we summarize the current knowledge on the expression of both PR isoforms in mammary glands, in experimental models of breast cancer and in breast cancer patients, to better understand how the PRA/PRB ratio can be exploited therapeutically to design personalized therapeutic strategies.
Fil: Lamb, Caroline Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Fabris, Victoria Teresa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Jacobsen, Britta M.. State University of Colorado - Fort Collins; Estados Unidos
Fil: Molinolo, Alfredo. University of California at San Diego; Estados Unidos
Fil: Lanari, Claudia Lee Malvina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina - Materia
-
BREAST CANCER
IN VIVO BREAST CANCER MODELS
ANTIPROGESTINS
ISOFORMS
PATIENT-DERIVED XENOGRAFTS
PR ISOFORM RATIO
PROGESTERONE RECEPTOR
PROGESTINS
PROGNOSTIC MARKERS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/85377
Ver los metadatos del registro completo
id |
CONICETDig_6fe8f46912b44cc1d7a9ebb74c65b44e |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/85377 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancerLamb, Caroline AnaFabris, Victoria TeresaJacobsen, Britta M.Molinolo, AlfredoLanari, Claudia Lee MalvinaBREAST CANCERIN VIVO BREAST CANCER MODELSANTIPROGESTINSISOFORMSPATIENT-DERIVED XENOGRAFTSPR ISOFORM RATIOPROGESTERONE RECEPTORPROGESTINSPROGNOSTIC MARKERShttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3There is a consensus that progestins and thus their cognate receptor molecules, the progesterone receptors (PRs), are essential in the development of the adult mammary gland and regulators of proliferation and lactation. However, a role for natural progestins in breast carcinogenesis remains poorly understood. A hint to that possible role came from studies in which the synthetic progestin medroxyprogesterone acetate was associated with an increased breast cancer risk in women under hormone replacement therapy. However, progestins have also been used for breast cancer treatment and to inhibit the growth of several experimental breast cancer models. More recently, PRs have been shown to be regulators of estrogen receptor signaling. With all this information, the question is how can we target PR, and if so, which patients may benefit from such an approach? PRs are not single unique molecules. Two main PR isoforms have been characterized, PRA and PRB, which exert different functions and the relative abundance of one isoform with respect to the other determines the response of PR agonists and antagonists. Immunohistochemistry with standard antibodies against PR do not discriminate between isoforms. In this review, we summarize the current knowledge on the expression of both PR isoforms in mammary glands, in experimental models of breast cancer and in breast cancer patients, to better understand how the PRA/PRB ratio can be exploited therapeutically to design personalized therapeutic strategies.Fil: Lamb, Caroline Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Fabris, Victoria Teresa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Jacobsen, Britta M.. State University of Colorado - Fort Collins; Estados UnidosFil: Molinolo, Alfredo. University of California at San Diego; Estados UnidosFil: Lanari, Claudia Lee Malvina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaBioScientifica2018-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/85377Lamb, Caroline Ana; Fabris, Victoria Teresa; Jacobsen, Britta M.; Molinolo, Alfredo; Lanari, Claudia Lee Malvina; Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer; BioScientifica; Endocrine - Related Cancer; 25; 12; 12-2018; R605-R6241351-0088CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://erc.bioscientifica.com/view/journals/erc/aop/erc-18-0179.xmlinfo:eu-repo/semantics/altIdentifier/doi/10.1530/ERC-18-0179info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:04:00Zoai:ri.conicet.gov.ar:11336/85377instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:04:01.261CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer |
title |
Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer |
spellingShingle |
Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer Lamb, Caroline Ana BREAST CANCER IN VIVO BREAST CANCER MODELS ANTIPROGESTINS ISOFORMS PATIENT-DERIVED XENOGRAFTS PR ISOFORM RATIO PROGESTERONE RECEPTOR PROGESTINS PROGNOSTIC MARKERS |
title_short |
Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer |
title_full |
Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer |
title_fullStr |
Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer |
title_full_unstemmed |
Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer |
title_sort |
Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer |
dc.creator.none.fl_str_mv |
Lamb, Caroline Ana Fabris, Victoria Teresa Jacobsen, Britta M. Molinolo, Alfredo Lanari, Claudia Lee Malvina |
author |
Lamb, Caroline Ana |
author_facet |
Lamb, Caroline Ana Fabris, Victoria Teresa Jacobsen, Britta M. Molinolo, Alfredo Lanari, Claudia Lee Malvina |
author_role |
author |
author2 |
Fabris, Victoria Teresa Jacobsen, Britta M. Molinolo, Alfredo Lanari, Claudia Lee Malvina |
author2_role |
author author author author |
dc.subject.none.fl_str_mv |
BREAST CANCER IN VIVO BREAST CANCER MODELS ANTIPROGESTINS ISOFORMS PATIENT-DERIVED XENOGRAFTS PR ISOFORM RATIO PROGESTERONE RECEPTOR PROGESTINS PROGNOSTIC MARKERS |
topic |
BREAST CANCER IN VIVO BREAST CANCER MODELS ANTIPROGESTINS ISOFORMS PATIENT-DERIVED XENOGRAFTS PR ISOFORM RATIO PROGESTERONE RECEPTOR PROGESTINS PROGNOSTIC MARKERS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
There is a consensus that progestins and thus their cognate receptor molecules, the progesterone receptors (PRs), are essential in the development of the adult mammary gland and regulators of proliferation and lactation. However, a role for natural progestins in breast carcinogenesis remains poorly understood. A hint to that possible role came from studies in which the synthetic progestin medroxyprogesterone acetate was associated with an increased breast cancer risk in women under hormone replacement therapy. However, progestins have also been used for breast cancer treatment and to inhibit the growth of several experimental breast cancer models. More recently, PRs have been shown to be regulators of estrogen receptor signaling. With all this information, the question is how can we target PR, and if so, which patients may benefit from such an approach? PRs are not single unique molecules. Two main PR isoforms have been characterized, PRA and PRB, which exert different functions and the relative abundance of one isoform with respect to the other determines the response of PR agonists and antagonists. Immunohistochemistry with standard antibodies against PR do not discriminate between isoforms. In this review, we summarize the current knowledge on the expression of both PR isoforms in mammary glands, in experimental models of breast cancer and in breast cancer patients, to better understand how the PRA/PRB ratio can be exploited therapeutically to design personalized therapeutic strategies. Fil: Lamb, Caroline Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Fabris, Victoria Teresa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Jacobsen, Britta M.. State University of Colorado - Fort Collins; Estados Unidos Fil: Molinolo, Alfredo. University of California at San Diego; Estados Unidos Fil: Lanari, Claudia Lee Malvina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina |
description |
There is a consensus that progestins and thus their cognate receptor molecules, the progesterone receptors (PRs), are essential in the development of the adult mammary gland and regulators of proliferation and lactation. However, a role for natural progestins in breast carcinogenesis remains poorly understood. A hint to that possible role came from studies in which the synthetic progestin medroxyprogesterone acetate was associated with an increased breast cancer risk in women under hormone replacement therapy. However, progestins have also been used for breast cancer treatment and to inhibit the growth of several experimental breast cancer models. More recently, PRs have been shown to be regulators of estrogen receptor signaling. With all this information, the question is how can we target PR, and if so, which patients may benefit from such an approach? PRs are not single unique molecules. Two main PR isoforms have been characterized, PRA and PRB, which exert different functions and the relative abundance of one isoform with respect to the other determines the response of PR agonists and antagonists. Immunohistochemistry with standard antibodies against PR do not discriminate between isoforms. In this review, we summarize the current knowledge on the expression of both PR isoforms in mammary glands, in experimental models of breast cancer and in breast cancer patients, to better understand how the PRA/PRB ratio can be exploited therapeutically to design personalized therapeutic strategies. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-12 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/85377 Lamb, Caroline Ana; Fabris, Victoria Teresa; Jacobsen, Britta M.; Molinolo, Alfredo; Lanari, Claudia Lee Malvina; Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer; BioScientifica; Endocrine - Related Cancer; 25; 12; 12-2018; R605-R624 1351-0088 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/85377 |
identifier_str_mv |
Lamb, Caroline Ana; Fabris, Victoria Teresa; Jacobsen, Britta M.; Molinolo, Alfredo; Lanari, Claudia Lee Malvina; Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer; BioScientifica; Endocrine - Related Cancer; 25; 12; 12-2018; R605-R624 1351-0088 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://erc.bioscientifica.com/view/journals/erc/aop/erc-18-0179.xml info:eu-repo/semantics/altIdentifier/doi/10.1530/ERC-18-0179 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
BioScientifica |
publisher.none.fl_str_mv |
BioScientifica |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269832068726784 |
score |
13.13397 |